share_log

Ancom Nylex To See Helm AG As Major Shareholder After Placement Exercise

Ancom Nylex To See Helm AG As Major Shareholder After Placement Exercise

Ancom將在配售行權後成爲Helm AG的主要股東
Business Today ·  09/23 08:22

Ancom Nylex Berhad has proposed to undertake a private placement of up to 10% of the total number of issued ordinary shares to German company Helm AG.

安康耐力克股份有限公司已提議進行定向增發,增發總股本的10%給德國公司赫爾姆股份有限公司。

The group said it had entered into a conditional placement agreement with HELM AG for the Proposed Private Placement at an issue price of RM1.00 per Ancom Nylex share. The Issue Price was determined based on the 5-day volume weighted average market price of its shares up to and including 20 September 2024 after adjusting for the distributions of approximately RM0.05 per share for the proposed second interim dividend of RM0.01 per share and proposed first interim dividend by way of distribution of treasury shares on the basis of 4 treasury shares for every 100 shares, representing approximately RM0.04 per share in respect of the financial year ending 31 May 2025 ("FY25").

集團表示已與赫爾姆股份有限公司簽訂了有條件的定向增發協議,每股安康耐力克股份的發行價格爲1.00馬幣。發行價格是基於其股票的5日成交量加權平均市價,並截至2024年9月20日,調整包括每股約0.05馬幣的擬議第二次臨時股息和每股0.01馬幣的擬議首次臨時股息的分配,以4股庫藏股配發每100股,約佔2025年5月31日結束的財政年度(「FY25」)每股0.04馬幣。

Upon completion of the Proposed Private Placement, HELM AG will emerge as a substantial major shareholder of Ancom Nylex.

經過定向增發的完成,赫爾姆股份有限公司將成爲安康耐力克的重要大股東。

Based on the Issue Price, the Proposed Private Placement is expected to raise gross proceeds of up to approximately RM96.2 million which the group aims RM56.0 million for the repayment of borrowings; RM39.2 million for general working purposes; RM1.0 million for the estimated expenses for the Proposed Private Placement.

根據發行價格,預計定向增發將籌集約9620萬馬幣的總收益,其中集團計劃用於償還借款5600萬馬幣;3920萬馬幣用於一般營運資金;100萬馬幣用於擬議定向增發的估計費用。

The Proposed Private Placement is expected to be completed by the fourth quarter of 2024 barring any unforeseen circumstances.

預計定向增發將於2024年第四季度完成,除非發生意外情況。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論